Complex movement disorders (CMDs), defined as disorders in which patients are affected by more than one movement disorder (such as parkinsonism and dystonia, or myoclonus and tremor), are a continuing challenge for diagnosis and treatment. CMDs are usually progressive, prevent patients from performing basic daily functions such as walking, eating, and talking, and result in high disease-associated financial and personal burden for patients and their families. Moreover, the already-known phenotypic and etiologic heterogeneity associated with movement disorder genes is quite striking and presents a significant challenge for treatment. Therefore, early diagnosis is crucial for appropriate treatment to restore motor activities and improve patients'quality of life. Since genetic studies in movement disorders (MDs) have demonstrated their success in the discovery of underlying pathologic processes and have helped researchers to understand both disease manifestation and progression, the identification of genetic factors underlying, or contributing to, the development of MDs provides a powerful tool for understanding their associated pathology. Accordingly, in an attempt to identify molecular networks associated with these CMDs and to facilitate novel treatments, this proposal focuses on the recruitment of familial and sporadic patients with CMDs, and the identification of their disease-causing alleles. Because whole exome sequencing (WES) has proved its ability to identify causative alleles for inherited diseases, even in families previously deemed statistically underpowered for positional cloning, and has become a fruitful strategy for gene identification in both Mendelian and more complex traits, WES, along with SNP-based arrays, which will reduce the search for causal variants, will be used for disease- causing mutation identification in this proposal. We believe that intense study of these disorders represents a powerful approach to elucidate disease mechanism for both CMDs and for more common disorders such as Parkinson's disease, and will lead to improvements in both diagnoses and treatments. In conclusion, this study will contribute enormously to the identification of novel CMD genes and the characterization of their phenotype, which not only are essential for understanding the etiology and pathophysiology of CMDs, but also for developing more targeted and efficient therapeutic strategies that will be of great benefit to human health.
The long-term goal of this proposal is to identify as many complex movement disorder (CMD) genes as possible and to define accurate genotype-phenotype correlations. Therefore, this proposal focuses on the recruitment of familial and sporadic patients with CMDs, and the identification of their disease-causing alleles. We believe that intense study of these disorders represents a powerful approach to elucidate disease mechanism for both CMDs and for more common disorders such as Parkinson's disease, and will lead to improvements in both diagnoses and treatments.
|Nirenberg, M J; Chaouni, R; Biller, T M et al. (2018) A novel TRPA1 variant is associated with carbamazepine-responsive cramp-fasciculation syndrome. Clin Genet 93:164-168|
|Wang, Jen-Chyong; Alinaghi, Somayeh; Tafakhori, Abbas et al. (2018) Genetic screening in two Iranian families with early-onset Alzheimer's disease identified a novel PSEN1 mutation. Neurobiol Aging 62:244.e15-244.e17|
|Darvish, Hossein; Bravo, Paloma; Tafakhori, Abbas et al. (2018) Identification of a large homozygous VPS13C deletion in a patient with early-onset Parkinsonism. Mov Disord 33:1968-1970|
|Taghavi, Shaghayegh; Chaouni, Rita; Tafakhori, Abbas et al. (2018) A Clinical and Molecular Genetic Study of 50 Families with Autosomal Recessive Parkinsonism Revealed Known and Novel Gene Mutations. Mol Neurobiol 55:3477-3489|
|Khodadadi, Hamidreza; Azcona, Luis J; Aghamollaii, Vajiheh et al. (2017) PTRHD1 (C2orf79) mutations lead to autosomal-recessive intellectual disability and parkinsonism. Mov Disord 32:287-291|
|Vilas, Dolores; Fernández-Santiago, Rubén; Sanchez, Elena et al. (2017) A Novel p.Glu298Lys Mutation in the ACMSD Gene in Sporadic Parkinson's Disease. J Parkinsons Dis 7:459-463|
|Darvish, Hossein; Azcona, Luis J; Tafakhori, Abbas et al. (2017) Whole genome sequencing identifies a novel homozygous exon deletion in the NT5C2 gene in a family with intellectual disability and spastic paraplegia. NPJ Genom Med 2:|
|Sanchez, Elena; Darvish, Hossein; Mesias, Roxana et al. (2016) Identification of a Large DNAJB2 Deletion in a Family with Spinal Muscular Atrophy and Parkinsonism. Hum Mutat 37:1180-1189|
|Bergareche, Alberto; Bednarz, Marcin; Sánchez, Elena et al. (2015) SCN4A pore mutation pathogenetically contributes to autosomal dominant essential tremor and may increase susceptibility to epilepsy. Hum Mol Genet 24:7111-20|
|Sánchez, Elena; Bergareche, Alberto; Krebs, Catharine E et al. (2015) SORT1 Mutation Resulting in Sortilin Deficiency and p75(NTR) Upregulation in a Family With Essential Tremor. ASN Neuro 7:|
Showing the most recent 10 out of 16 publications